drugset / Trial / NCT02081495
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to support the qualification of a replacement manufacturing site for DOXIL/CAELYX.
Timeline
- Start
- 2014-08
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |